Condition: Esophageal Squamous Cell Carcinoma · PD-1 Inhibitor · Sponsor: Nanfang Hospital, Southern Medical University
200 patients with advanced esophageal cancer who received PD-1 monoclonal antibody treatment would be enrolled in this study. Changes in peripheral blood immune cells before and after treatment would be recorded and used for machine learning to establish a prediction model for the efficacy of PD-1 monoclonal antibody treatment.
This description comes directly from the study's public registry record.
Shuai Chu · 18665000310 · shine9533@smu.edu.cn
Always discuss trial participation with your own doctor first.
| Nanfang Hospital | Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05392413